Avanos Medical (AVNS) Liabilities and Shareholders Equity (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 5.21% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.2 billion (down 24.13% YoY), and the FY2025 full-year result was $1.1 billion, down 6.97% from the prior year.
• Liabilities and Shareholders Equity fell to $1.1 billion in Q1 2026, from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q2 2025.
• A 5-year average of $1.5 billion and a median of $1.7 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity increased 11.43% in 2022 and slumped 37.33% in 2025, its largest moves.
• Tracing AVNS's Liabilities and Shareholders Equity over 5 years: stood at $1.8 billion in 2022, then slipped by 5.29% to $1.7 billion in 2023, then tumbled by 31.8% to $1.2 billion in 2024, then fell by 6.97% to $1.1 billion in 2025, then slipped by 2.2% to $1.1 billion in 2026.
• Business Quant data shows AVNS's Liabilities and Shareholders Equity at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.